Interleukin-10 (IL-10)

Interleukin-10 (IL-10) is a pivotal anti-inflammatory cytokine that serves as a master regulator of the immune response, primarily by inhibiting the synthesis of pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-12 (UniProt: P22301). It is produced by a variety of immune cells, including macrophages, B cells, and various T-cell subsets like Th2 and regulatory T cells (Tregs). By binding to its high-affinity heterotetrameric receptor complex, IL-10 initiates the JAK1/STAT3 signaling pathway, which leads to the transcriptional repression of inflammatory genes and the enhancement of anti-inflammatory mediators (NCBI Gene ID: 3586). In clinical pathology, IL-10 deficiency is strongly associated with early-onset inflammatory bowel disease, while its overexpression is often observed in tumors, where it can facilitate immune evasion by suppressing dendritic cell function. Therapeutic strategies involving IL-10 are dual-natured: recombinant forms (e.g., Ilodecakin) and long-acting PEGylated variants (e.g., Pegilodecakin) have been investigated for treating chronic inflammatory conditions and for their paradoxical ability to stimulate anti-tumor CD8+ T-cell immunity in solid tumors (PMID: 30249030). Despite its therapeutic potential, challenges remain regarding its narrow therapeutic window and the risk of systemic side effects such as hematological toxicities.

Other names

Cytokine synthesis inhibitory factorCSIFIL10ATGIFGVHDS

Drugs targeting Interleukin-10 typically act as agonists of the IL-10 receptor complex (IL-10RA and IL-10RB) to activate the JAK1/STAT3 signaling pathway, thereby suppressing pro-inflammatory cytokine production (e.g., TNF-alpha, IL-12) (PMID: 11163118). Conversely, in oncology, IL-10 agonists like Pegilodecakin are used to stimulate the expansion and cytotoxic activity of CD8+ T-cells within the tumor microenvironment (DrugBank: DB12880). Neutralizing antibodies (e.g., BT-063) aim to block IL-10 to enhance immune responses in chronic infections or specific cancers.